Abstract
The ribonucleoprotein, telomerase, prevents genomic instability by adding telomere repeats at the end of chromosomes. Although the telomerase RNA component (TERC) is ubiquitously expressed in mammalian cells, the telomerase reverse transcriptase subunit (TERT) is not expressed at easily detectable levels in most somatic cells but is expressed in most cancer cells. Targeting the up-regulation of TERT expression and/or enzymatic activity has gained considerable attention as a potential cancer therapy. Agents targeting the TERT component include nucleoside and nonnucleoside analogs as well as molecular inhibition of TERT using dominant negative protein expression or by ribozymes. Expression of the RNA component of telomerase has been targeted using RNA oligonucleotides. Additionally, peptide vaccines against telomerase have also been studied. Although several telomerase inhibitors have begun initial clinical trials for cancer therapy, none so far have entered clinical practice. Several aspects of telomere biology and telomerase action must be considered in designing anti-telomerase strategies for cancer treatment. These include expression of telomerase in normal somatic cells, the potential for selection of ALT (alternative lengthening of telomeres) clones, and the time-lag that is observed between initiation of treatment and appearance of cytopathic effect. However, knowledge of telomerase functions beyond telomere maintenance can provide insight into methods that may overcome limitations of telomerase- based therapies.
Keywords: Telomerase, telomeres, cancer therapy, anti-telomerase agents
Current Cancer Therapy Reviews
Title: Targeting Telomerase for Cancer Therapy
Volume: 7 Issue: 3
Author(s): Shivani Ruparel, Aisha Siddiqa and Robert A. Marciniak
Affiliation:
Keywords: Telomerase, telomeres, cancer therapy, anti-telomerase agents
Abstract: The ribonucleoprotein, telomerase, prevents genomic instability by adding telomere repeats at the end of chromosomes. Although the telomerase RNA component (TERC) is ubiquitously expressed in mammalian cells, the telomerase reverse transcriptase subunit (TERT) is not expressed at easily detectable levels in most somatic cells but is expressed in most cancer cells. Targeting the up-regulation of TERT expression and/or enzymatic activity has gained considerable attention as a potential cancer therapy. Agents targeting the TERT component include nucleoside and nonnucleoside analogs as well as molecular inhibition of TERT using dominant negative protein expression or by ribozymes. Expression of the RNA component of telomerase has been targeted using RNA oligonucleotides. Additionally, peptide vaccines against telomerase have also been studied. Although several telomerase inhibitors have begun initial clinical trials for cancer therapy, none so far have entered clinical practice. Several aspects of telomere biology and telomerase action must be considered in designing anti-telomerase strategies for cancer treatment. These include expression of telomerase in normal somatic cells, the potential for selection of ALT (alternative lengthening of telomeres) clones, and the time-lag that is observed between initiation of treatment and appearance of cytopathic effect. However, knowledge of telomerase functions beyond telomere maintenance can provide insight into methods that may overcome limitations of telomerase- based therapies.
Export Options
About this article
Cite this article as:
Ruparel Shivani, Siddiqa Aisha and A. Marciniak Robert, Targeting Telomerase for Cancer Therapy, Current Cancer Therapy Reviews 2011; 7 (3) . https://dx.doi.org/10.2174/157339411796234870
DOI https://dx.doi.org/10.2174/157339411796234870 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the G2/M Transition for Antitumor Therapy
Letters in Drug Design & Discovery Multidisciplinary Treatment of Early Stage Endometrial Cancer
Anti-Cancer Agents in Medicinal Chemistry Virus, Oncolytic Virus and Human Prostate Cancer
Current Cancer Drug Targets Synthetic Lethality and PARP-Inhibitors in Oral and Head & Neck Cancer
Current Pharmaceutical Design Organosulphur Compounds Induce Apoptosis and Cell Cycle Arrest in Cervical Cancer Cells via Downregulation of HPV E6 and E7 Oncogenes
Anti-Cancer Agents in Medicinal Chemistry A Genetic Dissection of Antipsychotic Induced Movement Disorders
Current Medicinal Chemistry Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design NAD Biosynthesis in Humans - Enzymes, Metabolites and Therapeutic Aspects
Current Topics in Medicinal Chemistry In Silico Prediction and Validation of Oxygen-Regulated Protein N-myc Downstream Regulated Gene 3 and Virtual Screening of Competitive Inhibitors of L-Lactate as Therapeutics
Letters in Drug Design & Discovery Gene Therapy and Cell Reprogramming For the Aging Brain: Achievements and Promise
Current Gene Therapy DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry Bioactive Components and Pharmacological Action of Wikstroemia indica (L.) C. A. Mey and Its Clinical Application
Current Pharmaceutical Biotechnology Scope of Nanotechnology-based Radiation Therapy and Thermotherapy Methods in Cancer Treatment
Current Cancer Drug Targets Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry Pharmaceutical Applications of Graphene-based Nanosheets
Current Pharmaceutical Biotechnology Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
Current Medicinal Chemistry Yin and Yang of Polyphenols in Cancer Prevention: A Short Review
Anti-Cancer Agents in Medicinal Chemistry